Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering

Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering

Abstract Allogeneic Vγ9Vδ2 (Vδ2) T cells have emerged as attractive candidates for developing cancer therapy due to their established safety in allogeneic contexts and inherent tumor-fighting capabilities. Nonetheless, the limited clinical success of Vδ2 T cell-based treatments may be attributed to...

Full description

Bibliographic Details
Main Authors: Derek Lee, Zachary Spencer Dunn, Wenbin Guo, Carl J. Rosenthal, Natalie E. Penn, Yanqi Yu, Kuangyi Zhou, Zhe Li, Feiyang Ma, Miao Li, Tsun-Ching Song, Xinjian Cen, Yan-Ruide Li, Jin J. Zhou, Matteo Pellegrini, Pin Wang, Lili Yang
Format: Article
Language:English
Published: Nature Portfolio 2023-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-42619-2

Internet

https://doi.org/10.1038/s41467-023-42619-2

Similar Items